BLOOD CANCER UNITED INC: Form 990, tax year 2017

View the entire original 990 at ProPublica ↗

Organization
BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period
2017-07-01 to 2018-06-30
Filed
2019-02-27
IRS object ID
201920589349300912
Schema version
2017v2.3
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2019-02-27T11:12:58-06:00ReturnTs
Tax Period End2018-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135565207PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1345 PARK AVENUEAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP101540102ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2017-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN135644916EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE LEUKEMIA & LYMPHOMA SOCIETYINCBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlLEUKBusinessNameControlTxt
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonGORDON MILLER JRPersonNm
Person TitleSVP FINANCEPersonTitleTxt
Phone9148218908PhoneNum
Signature2019-02-04SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonDAVID M HIGHFILLPreparerPersonNm
PTINP01517891PTIN
Phone2127589700PhoneNum
Preparation2019-02-27PreparationDt

Filing Security Information FilingSecurityInformation

IP Address IPAddress

FieldValueIRS element (for citing)
I Pv4 Address172.85.47.202IPv4AddressTxt
FieldValueIRS element (for citing)
IP2019-02-27IPDt
IP Tm11:12:58IPTm
IP TimezoneCSIPTimezoneCd
Filing License TypePFilingLicenseTypeCd
At Submission Creation Device Id5169B9C1869B4BD13DE3B279716107AD2954B893AtSubmissionCreationDeviceId
At Submission Filing Device Id5169B9C1869B4BD13DE3B279716107AD2954B893AtSubmissionFilingDeviceId
FieldValueIRS element (for citing)
Tax2017TaxYr
Build TS2019-02-21 02:37:17ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerLOUIS J DEGENNAROPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVE SUITE 200AddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$509,256,601GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.LLS.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1949FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.ActivityOrMissionDesc
Voting Members Governing Body24VotingMembersGoverningBodyCnt
Voting Members Independent23VotingMembersIndependentCnt
Total Employee1291TotalEmployeeCnt
Total Volunteers3000000TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
PY Contributions Grants$314,912,814PYContributionsGrantsAmt
CY Contributions Grants$419,570,497CYContributionsGrantsAmt
PY Program Service Revenue$3,847,456PYProgramServiceRevenueAmt
CY Program Service Revenue$9,230,125CYProgramServiceRevenueAmt
PY Investment Income$1,121,864PYInvestmentIncomeAmt
CY Investment Income$9,920,211CYInvestmentIncomeAmt
PY Other Revenue$25,416,466PYOtherRevenueAmt
CY Other Revenue$133,928CYOtherRevenueAmt
PY Total Revenue$345,298,600PYTotalRevenueAmt
CY Total Revenue$438,854,761CYTotalRevenueAmt
PY Grants And Similar Paid$122,873,965PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$157,849,965CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$97,808,057PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$104,079,229CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$4,046,893PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$5,748,936CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$45,741,999CYTotalFundraisingExpenseAmt
PY Other Expenses$90,757,098PYOtherExpensesAmt
CY Other Expenses$88,772,222CYOtherExpensesAmt
PY Total Expenses$315,486,013PYTotalExpensesAmt
CY Total Expenses$356,450,352CYTotalExpensesAmt
PY Revenues Less Expenses$29,812,587PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$82,404,409CYRevenuesLessExpensesAmt
Total Assets BOY$272,265,949TotalAssetsBOYAmt
Total Assets EOY$382,344,839TotalAssetsEOYAmt
Total Liabilities BOY$119,978,224TotalLiabilitiesBOYAmt
Total Liabilities EOY$146,112,465TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$152,287,725NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$236,232,374NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.MissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$64,124,010ExpenseAmt
Grant$47,400,064GrantAmt
Revenue$9,230,125RevenueAmt
DescA) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.2 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. (CONTINUED ON SCHEDULE O) WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2018, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 47 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA(AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. LLS EXPECTS UP TO 500 PATIENTS TO ENROLL IN THE TRIAL. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2018, FOR THE SEDesc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$160,694,033ExpenseAmt
Grant$110,449,901GrantAmt
DescB) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.3 MILLION PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE (CONTINUED ON SCHEDULE O) PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2018, 621,651 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 7,449 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 102,125 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2018, A COMBINED 110,449,901 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAMS (108,442,482) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (2,007,419). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2018, 108,442,482 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 29,898 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2018. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2018, 2,007,419 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 4,772 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2018. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2018, 10 BCC CONFERENCES WERE HELD WITH 3,220 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2018, THERE WERE APPROXIMATELY 8,000 COMMUNITY MEMBERS AND 69,532 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 41,000 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2018 LLS SUPPORTED OR HOSTED 113 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2018, 3,382 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,300 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2018.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$39,795,810ExpenseAmt
DescC) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS MAY ALSO REFER PATIENTS AND CAREGIVERS TO A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER. THE NURSES IN THIS CENTER HAVE EXPERTISE IN THE BLOOD CANCERS AND PROVIDE PATIENTS AND THEIR (CONTINUED ON SCHEDULE O) CAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2018: - 18,453 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 12,643 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -562 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 60% OF MEDICALLY ELIGIBLE PATIENTS ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 18 NEARLY 1000 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2018: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 5,572 PARTICIPANTS -THERE WERE 29,756 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 12,004 VIRTUAL LECTURE VIEWS; 6,801 PODCAST DOWNLOADS; AND 32,708 VIDEO VIEWS. -LLS LAUNCHED A NEW PODCAST, "THE BLOODLINE WITH LLS," WHICH REACHED MORE THAN 7,000 LISTENERS AND COVERED A RANGE OF TOPICS THAT MATTER MOST TO PATIENTS AND CAREGIVERS, FROM CANCER-RELATED FATIGUE TO COMMUNICATING EFFECTIVELY WITH CANCER CARE TEAMS.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

FieldValueIRS element (for citing)
Expense$17,206,016ExpenseAmt
DescD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2018: -LLS PROVIDED 11 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 1,981 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 18,503 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 12,919 VIRTUAL LECTURE VIEWS; AND 3,775 ONLINE VIDEO VIEWS FOR PROFESSIONALS.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$17,206,016TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses$281,819,869TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesYes (true)LobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtYes (true)CollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Temp Or Permanent EndowmentsYes (true)TempOrPermanentEndowmentsInd
Report Land Building EquipmentYes (true)ReportLandBuildingEquipmentInd
Report Investments Other SecfalseReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsfalseReportOtherAssetsInd
Report Other LiabilitiesfalseReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (true)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtfalseIndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtYes (true)ConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficeYes (true)ForeignOfficeInd
Foreign ActivitiesYes (true)ForeignActivitiesInd
More Than5000 K To OrgYes (true)MoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingYes (true)ProfessionalFundraisingInd
Fundraising ActivitiesYes (true)FundraisingActivitiesInd
Gaming ActivitiesYes (true)GamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsYes (true)GrantsToOrganizationsInd
Grants To IndividualsYes (true)GrantsToIndividualsInd
Schedule J RequiredYes (true)ScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemYes (true)BusinessRlnWithFamMemInd
Business Rln With Officer EntfalseBusinessRlnWithOfficerEntInd
Deductible Non Cash ContriYes (true)DeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityYes (true)DisregardedEntityInd
Related EntityYes (true)RelatedEntityInd
Related Organization Ctrl EntYes (true)RelatedOrganizationCtrlEntInd
Transaction With Control EntYes (true)TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd OrgfalseTrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
IRP Document698IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee1291EmployeeCnt
Employment Tax Returns FiledYes (true)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountYes (true)ForeignFinancialAccountInd
Foreign CountryCAForeignCountryCd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsYes (true)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (true)QuidProQuoContriDisclInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members24GoverningBodyVotingMembersCnt
Independent Voting Member23IndependentVotingMemberCnt
Family Or Business RlnfalseFamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsfalseChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersYes (true)MembersOrStockholdersInd
Election Of Board MembersYes (true)ElectionOfBoardMembersInd
Decisions Subject To ApprovaYes (true)DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (true)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (true)MinutesOfCommitteesInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersYes (true)LocalChaptersInd
Policies Reference ChaptersYes (true)PoliciesReferenceChaptersInd
Form990 Provided To Gvrn BodyYes (true)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (true)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (true)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (true)WhistleblowerPolicyInd
Document Retention PolicyYes (true)DocumentRetentionPolicyInd
Compensation Process CEOYes (true)CompensationProcessCEOInd
Compensation Process OtherYes (true)CompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
States Where Copy Of Return Is FldAKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldAZStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldIDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldINStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldLAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPRStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonGORDON MILLER JRPersonNm
Phone9148218935PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (38 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeIndIndividual Trustee Or DirectorIndividualTrusteeOrDirectorInd
LOUIS J DEGENNARO
PRESIDENT &40.001.00Yes (X)$634,681$0$38,606
ROSEMARIE A LOFFREDO
EVP - CFO40.001.00Yes (X)$380,439$0$20,611
GORDON MILLER JR
SVP FINANCE40.001.00Yes (X)$270,092$0$38,512
ANDREW S COCCARI
EVP CHIEF PR40.00$357,087$0$38,617Yes (X)
ALICE O'ROURKE
EVP CHIEF DE40.00$353,639$0$39,437Yes (X)
GWEN NICHOLS
EVP CHIEF ME40.00$377,104$0$22,429Yes (X)
KATHY GRISENBECK
EVP CHIEF RE40.00$324,213$0$35,004Yes (X)
LEE M GREENBERGER
SVP CHIEF SC40.00$329,689$0$42,400Yes (X)
CLAUDE EDKINS - END 3312017
VP INFORMATI40.00$354,386$0$14,323Yes (X)
MARCIE KLEIN
EVP, COMMUNI40.00$266,288$0$30,959Yes (X)
ELISA WEISS
SVP PAT ACCE40.00$257,147$0$26,656Yes (X)
CARSON JACOBI
SVP, HEALTHC40.00$251,004$0$31,039Yes (X)
PETER B BROCK
CHAIR6.002.00Yes (X)$0$0$0Yes (X)
JORGE L BENITEZ
VICE CHAIR4.002.00Yes (X)$0$0$0Yes (X)
RALPH E LAWSON
SECRETARY/TR4.002.00Yes (X)$0$0$0Yes (X)
BART SICHEL
AT LARGE4.002.00Yes (X)$0$0$0Yes (X)
WILLIAM G BEHNKE
BOD MEMBER4.00$0$0$0Yes (X)
A DANA CALLOW JR
BOD MEMBER4.00$0$0$0Yes (X)
RENZO CANETTA MD
BOD MEMBER4.00$0$0$0Yes (X)
ELIZABETH J CLARK PHD
BOD MEMBER4.00$0$0$0Yes (X)
WILLIAM S DALTON PHD
BOD MEMBER4.00$0$0$0Yes (X)
BERNARD H GARIL
BOD MEMBER4.00$0$0$0Yes (X)
FRANCIE HELLER
BOD MEMBER4.00$0$0$0Yes (X)
JOSEPH B KELLEY
BOD MEMBER4.00$0$0$0Yes (X)
MARY KENNARD - END JUNE 12 2018
BOD MEMBER4.00$0$0$0Yes (X)
MICHELLE LE BEAU PHD
BOD MEMBER4.00$0$0$0Yes (X)
CONNIE L LINDSEY
BOD MEMBER4.00$0$0$0Yes (X)
KATHLEEN MERIWETHER
BOD MEMBER4.00$0$0$0Yes (X)
TED MOROZ
BOD MEMBER4.00$0$0$0Yes (X)
LYNNE O'BRIEN
BOD MEMBER4.00$0$0$0Yes (X)
MARLA PERSKY
BOD MEMBER4.00$0$0$0Yes (X)
DONALD PROCTOR
BOD MEMBER4.00$0$0$0Yes (X)
ROBERT ROSEN
BOD MEMBER4.00$0$0$0Yes (X)
STEVEN T ROSEN
BOD MEMBER4.00$0$0$0Yes (X)
JEFF SACHS
BOD MEMBER4.00$0$0$0Yes (X)
KENNETH M SCHWARTZ
BOD MEMBER4.00$0$0$0Yes (X)
FRANK SMITH - END FEB 1 2018
BOD MEMBER4.00$0$0$0Yes (X)
KEITH S WHITE
BOD MEMBER4.00$0$0$0Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$4,155,769TotalReportableCompFromOrgAmt
Total Other Compensation$378,593TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K187IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedfalseFormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (true)TotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
INC RESEARCH LLC
75 REMITTANCE DRIVE SUITE 3160CHICAGOIL606753160CLINICAL TRIAL$7,600,357
PATIENT ADVOCACY FOUNDATION
421 BUTLER FARM RDHAMPTONVA23666PAT ASSIST PROC$6,567,690
RESOURCE ONE
2900 EAST APACHE STREETTULSAOK74110DIRECT MARKETIN$6,070,357
TARGETCW
9475 CHESEPAKE DRIVESAN DIEGOCA92123TEMP STAFFING$3,867,319
NORTHGATE DIGITAL CORPORATION
301 SOUTH STATE STREET SUITE N-200NEWTOWNPA189401956SOFTWARE DEVELO$2,906,258
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K146CntrctRcvdGreaterThan100KCnt
Info In Schedule O Part VIIIYes (X)InfoInScheduleOPartVIIIInd
Federated Campaigns$1,238,625FederatedCampaignsAmt
Fundraising$174,170,889FundraisingAmt
All Other Contributions$244,160,983AllOtherContributionsAmt
Noncash Contributions$4,566,056NoncashContributionsAmt
Total Contributions$419,570,497TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescSERVICE REVENUEDesc
Business541900BusinessCd
Total Revenue Column$9,230,125TotalRevenueColumnAmt
Related Or Exempt Func Income$9,230,125RelatedOrExemptFuncIncomeAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$9,230,125TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$4,381,670TotalRevenueColumnAmt
Exclusion$4,381,670ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$3,854,315TotalRevenueColumnAmt
Exclusion$3,854,315ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$47,607,399SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$42,068,858SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$5,538,541SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$5,538,541TotalRevenueColumnAmt
Exclusion$5,538,541ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$23,982,308FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$174,170,889ContriRptFundraisingEventAmt
Fundraising Direct Expenses$28,105,749FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$4,123,441TotalRevenueColumnAmt
Exclusion-$4,123,441ExclusionAmt
FieldValueIRS element (for citing)
Gaming Gross Income$560,287GamingGrossIncomeAmt
Gaming Direct Expenses$227,233GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

FieldValueIRS element (for citing)
Total Revenue Column$333,054TotalRevenueColumnAmt
Exclusion$333,054ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp

FieldValueIRS element (for citing)
DescOTHER MISCELLANEOUSDesc
Business900099BusinessCd
Total Revenue Column$70,000TotalRevenueColumnAmt
Exclusion$70,000ExclusionAmt
FieldValueIRS element (for citing)
Other Revenue Total$70,000OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$438,854,761TotalRevenueColumnAmt
Related Or Exempt Func Income$9,230,125RelatedOrExemptFuncIncomeAmt
Exclusion$10,054,139ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$40,792,965TotalAmt
Program Services$40,792,965ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$110,449,901TotalAmt
Program Services$110,449,901ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$6,607,099TotalAmt
Program Services$6,607,099ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$2,710,622TotalAmt
Program Services$1,681,862ProgramServicesAmt
Management And General$485,583ManagementAndGeneralAmt
Fundraising$543,177FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$82,813,099TotalAmt
Program Services$51,395,278ProgramServicesAmt
Management And General$14,893,616ManagementAndGeneralAmt
Fundraising$16,524,205FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$2,267,194TotalAmt
Program Services$1,402,356ProgramServicesAmt
Management And General$385,162ManagementAndGeneralAmt
Fundraising$479,676FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$10,397,109TotalAmt
Program Services$6,431,056ProgramServicesAmt
Management And General$1,766,311ManagementAndGeneralAmt
Fundraising$2,199,742FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$5,891,205TotalAmt
Program Services$3,643,962ProgramServicesAmt
Management And General$1,000,826ManagementAndGeneralAmt
Fundraising$1,246,417FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$1,084,438TotalAmt
Program Services$777,839ProgramServicesAmt
Management And General$129,137ManagementAndGeneralAmt
Fundraising$177,462FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$358,738TotalAmt
Program Services$257,313ProgramServicesAmt
Management And General$42,719ManagementAndGeneralAmt
Fundraising$58,706FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$686,929TotalAmt
Program Services$492,716ProgramServicesAmt
Management And General$81,801ManagementAndGeneralAmt
Fundraising$112,412FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$5,748,936TotalAmt
Fundraising$5,748,936FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$318,629TotalAmt
Program Services$196,795ProgramServicesAmt
Management And General$61,210ManagementAndGeneralAmt
Fundraising$60,624FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$19,806,356TotalAmt
Program Services$14,206,574ProgramServicesAmt
Management And General$2,358,584ManagementAndGeneralAmt
Fundraising$3,241,198FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$7,220,365TotalAmt
Program Services$3,668,782ProgramServicesAmt
Management And General$824,733ManagementAndGeneralAmt
Fundraising$2,726,850FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$18,634,663TotalAmt
Program Services$10,151,479ProgramServicesAmt
Management And General$1,917,567ManagementAndGeneralAmt
Fundraising$6,565,617FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$7,321,496TotalAmt
Program Services$5,251,515ProgramServicesAmt
Management And General$871,860ManagementAndGeneralAmt
Fundraising$1,198,121FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$9,096,024TotalAmt
Program Services$6,022,346ProgramServicesAmt
Management And General$1,269,131ManagementAndGeneralAmt
Fundraising$1,804,547FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$7,034,959TotalAmt
Program Services$4,839,364ProgramServicesAmt
Management And General$1,114,311ManagementAndGeneralAmt
Fundraising$1,081,284FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$5,401,215TotalAmt
Program Services$3,579,240ProgramServicesAmt
Management And General$882,566ManagementAndGeneralAmt
Fundraising$939,409FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$720,360TotalAmt
Program Services$514,432ProgramServicesAmt
Management And General$99,631ManagementAndGeneralAmt
Fundraising$106,297FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
RESEARCH AND DEVELOPMENT$5,898,507$5,898,507
MISCELLANEOUS$5,189,543$3,558,488$703,736$927,319

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$356,450,352TotalAmt
Program Services$281,819,869ProgramServicesAmt
Management And General$28,888,484ManagementAndGeneralAmt
Fundraising$45,741,999FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$12,830,983TotalAmt
Program Services$7,313,910ProgramServicesAmt
Fundraising$5,517,073FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$37,250,666BOYAmt
EOY$26,473,618EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$62,751,205BOYAmt
EOY$157,894,948EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$16,228,169BOYAmt
EOY$32,009,273EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$3,425,491BOYAmt
EOY$2,530,972EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$45,035,188LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$36,560,960LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$9,987,844BOYAmt
EOY$8,474,228EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$133,187,861BOYAmt
EOY$145,134,605EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$9,434,713BOYAmt
EOY$9,827,195EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$272,265,949BOYAmt
EOY$382,344,839EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$24,296,564BOYAmt
EOY$25,315,604EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$82,120,581BOYAmt
EOY$105,033,884EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$13,561,079BOYAmt
EOY$15,762,977EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$119,978,224BOYAmt
EOY$146,112,465EOYAmt
FieldValueIRS element (for citing)
Organization Follows SFAS117Yes (X)OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

FieldValueIRS element (for citing)
BOY$120,968,910BOYAmt
EOY$143,923,113EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$28,432,696BOYAmt
EOY$89,422,942EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

FieldValueIRS element (for citing)
BOY$2,886,119BOYAmt
EOY$2,886,319EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$152,287,725BOYAmt
EOY$236,232,374EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$272,265,949BOYAmt
EOY$382,344,839EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss$82,404,409ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$1,802,359NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets-$262,119OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewfalseAccountantCompileOrReviewInd
FS AuditedYes (true)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (true)AuditCommitteeInd
Federal Grant Audit RequiredfalseFederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$302,437,152CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$283,909,984CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$285,638,088CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$314,912,814CurrentTaxYearMinus1YearAmt
Current Tax Year$419,570,497CurrentTaxYearAmt
Total$1,606,468,535TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$302,437,152CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$283,909,984CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$285,638,088CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$314,912,814CurrentTaxYearMinus1YearAmt
Current Tax Year$419,570,497CurrentTaxYearAmt
Total$1,606,468,535TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$348,621,259SubstantialContributorsTotAmt
Public Support Total170$1,257,847,276PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,203,865CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,891,412CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,565,846CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$7,018,822CurrentTaxYearMinus1YearAmt
Current Tax Year$8,235,985CurrentTaxYearAmt
Total$19,915,930TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$104,879CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$56,829CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$19,529CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$25,439,044CurrentTaxYearMinus1YearAmt
Current Tax Year$70,000CurrentTaxYearAmt
Total$25,690,281TotalAmt
FieldValueIRS element (for citing)
Total Support$1,652,074,746TotalSupportAmt
Gross Receipts Rltd Activities$108,052,973GrossReceiptsRltdActivitiesAmt
Public Support CY1700.76140PublicSupportCY170Pct
Public Support PY1700.80950PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferencePART II, LINE 10FormAndLineReferenceDesc
ExplanationOTHER MISC. REVENUE (YR 2013-2017) 370,085 TAP CONTRACTUAL RETURN (YR 2016) 25,320,196ExplanationTxt

Schedule B IRS990ScheduleB

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
VolunteersYes (true)VolunteersInd
Paid Staff Or ManagementYes (true)PaidStaffOrManagementInd
Media AdvertisementsfalseMediaAdvertisementsInd
Mailings MembersfalseMailingsMembersInd
Publications Or BroadcastYes (true)PublicationsOrBroadcastInd
Publications Or Broadcast$196,761PublicationsOrBroadcastAmt
Grants Other OrganizationsfalseGrantsOtherOrganizationsInd
Direct Contact LegislatorsYes (true)DirectContactLegislatorsInd
Direct Contact Legislators$296,800DirectContactLegislatorsAmt
Rallies DemonstrationsYes (true)RalliesDemonstrationsInd
Rallies Demonstrations$233,151RalliesDemonstrationsAmt
Other ActivitiesYes (true)OtherActivitiesInd
Other Activities$398,846OtherActivitiesAmt
Total Lobbying Expenditures$1,125,558TotalLobbyingExpendituresAmt
Not Described Section501c3falseNotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE C, PART II-B, LINE 1FormAndLineReferenceDesc
ExplanationLLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL, AMERICAN CHILDHOOD CANCER ORGANIZATION, PUBLIC AFFAIRS COUNCIL, PATIENT QUALITY OF LIFE COALITION, DEFENSE HEALTH RESEARCH CONSORTIUM, AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.ExplanationTxt

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Collection Used Pub ExhibitionYes (X)CollectionUsedPubExhibitionInd
Solicited Assets SalefalseSolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$5,897,377BeginningYearBalanceAmt
Contributions$200ContributionsAmt
Investment Earnings Or Losses$546,324InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$237,896GrantsOrScholarshipsAmt
Administrative Expenses-$13,198AdministrativeExpensesAmt
End Year Balance$6,192,807EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,027,967BeginningYearBalanceAmt
Contributions$5,200ContributionsAmt
Investment Earnings Or Losses$119,369InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$240,000GrantsOrScholarshipsAmt
Administrative Expenses-$15,159AdministrativeExpensesAmt
End Year Balance$5,897,377EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,115,645BeginningYearBalanceAmt
Contributions$45,095ContributionsAmt
Investment Earnings Or Losses$116,288InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$240,000GrantsOrScholarshipsAmt
Administrative Expenses-$9,060AdministrativeExpensesAmt
End Year Balance$6,027,967EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,122,698BeginningYearBalanceAmt
Investment Earnings Or Losses$218,549InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$221,499GrantsOrScholarshipsAmt
Administrative Expenses-$4,103AdministrativeExpensesAmt
End Year Balance$6,115,645EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,027,657BeginningYearBalanceAmt
Investment Earnings Or Losses$313,872InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$215,000GrantsOrScholarshipsAmt
Administrative Expenses-$3,831AdministrativeExpensesAmt
End Year Balance$6,122,698EndYearBalanceAmt
FieldValueIRS element (for citing)
Prmnnt Endowment Balance EOY0.46610PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY0.53390TermEndowmentBalanceEOYPct
Endowments Held Unrelated OrgfalseEndowmentsHeldUnrelatedOrgInd
Endowments Held Related OrgfalseEndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$1,843,395OtherCostOrOtherBasisAmt
Depreciation$1,103,166DepreciationAmt
Book Value$740,229BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$38,720,647OtherCostOrOtherBasisAmt
Depreciation$32,166,803DepreciationAmt
Book Value$6,553,844BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$4,471,146OtherCostOrOtherBasisAmt
Depreciation$3,290,991DepreciationAmt
Book Value$1,180,155BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$8,474,228TotalBookValueLandBuildingsAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$456,235,844TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$1,802,359NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$6,231,494DonatedServicesAndUseFcltsAmt
Other Revenue$9,455,128OtherRevenueAmt
Revenue Not Reported$17,488,981RevenueNotReportedAmt
Revenue Subtotal$438,746,863RevenueSubtotalAmt
Investment Expenses Not Incld$37,898InvestmentExpensesNotIncldAmt
Other Revenues Not Included$70,000OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt$107,898RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$438,854,761TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$372,974,486TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$6,231,494DonatedServicesUseFcltsAmt
Other Expenses Included$10,231,369OtherExpensesIncludedAmt
Expenses Not Reported$16,462,863ExpensesNotReportedAmt
Expenses Subtotal$356,511,623ExpensesSubtotalAmt
Investment Expenses Not Incld2$37,898InvestmentExpensesNotIncld2Amt
Other Expenses Not Included-$99,169OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt-$61,271ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$356,450,352TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (7 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE D, PAGE 2, PART III, LINE 4THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART XLLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2018 AND 2017.
SCHEDULE D, PAGE 4, PART XI, LINE 2DLLS CANADA REVENUE 9,320,767 PEARLPOINT CANCER SUPPORT REVENUE 134,361
SCHEDULE D, PAGE 4, PART XI, LINE 4BPEARLPOINT MANAGEMENT FEES 70,000
SCHEDULE D, PAGE 4, PART XII, LINE 2DLLS CANADA EXPENSES 9,952,411 PEARLPOINT CANCER SUPPORT EXPENSES 276,316 ROUNDING 2,642
SCHEDULE D, PAGE 4, PART XII, LINE 4BLLS CANADA FOREIGN CURRENCY ADJ -99,169

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)

RegionRegionTxtOfficesOfficesCntEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmt
NORTH AMERICA77RESEARCH FUNDINGRESEARCH GRANTS$1,910,000
EUROPE6RESEARCH FUNDINGRESEARCH GRANTS$1,550,926
EUROPE1INVESTMENTSINVESTMENTS$3,576,257
EAST ASIA5RESEARCH FUNDINGRESEARCH GRANTS$2,826,172
CENTRAL AMERICA & CARIBBEAN1INVESTMENTSINVESTMENTS$1,735,772
MIDDLE EAST & NORTH AFRICA1RESEARCH FUNDINGRESEARCH GRANTS$120,000
FieldValueIRS element (for citing)
Subtotal Offices7SubtotalOfficesCnt
Subtotal Employees21SubtotalEmployeesCnt
Total Office7TotalOfficeCnt
Total Employee21TotalEmployeeCnt
Subtotal Spent$11,719,127SubtotalSpentAmt
Total Spent$11,719,127TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (21 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtValuation Method UsedValuationMethodUsedDesc
NORTH AMERICARESEARCH GRANT$60,000CHECKACCRUAL
EUROPERESEARCH GRANT$199,758WIREACCRUAL
EUROPERESEARCH GRANT$200,000WIREACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$200,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$75,000CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$200,000WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$199,996CHECKACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$67,000WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$100,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$1,000,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$75,000CHECKACCRUAL
NORTH AMERICARESEARCH GRANT$300,000CHECKACCRUAL
EUROPERESEARCH GRANT$333,333WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$60,000WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$199,176WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$2,000,000WIREACCRUAL
MIDDLE EAST & NORTH AFRICARESEARCH GRANT$120,000WIREACCRUAL
EUROPERESEARCH GRANT$67,795WIREACCRUAL
EUROPETHERAPY ACCELERATION$250,040WIREFMV
EUROPETHERAPY ACCELERATION$500,000WIREFMV
FieldValueIRS element (for citing)
Total Other Org16TotalOtherOrgCnt
Transfer To Foreign CorpfalseTransferToForeignCorpInd
Interest In Foreign TrustfalseInterestInForeignTrustInd
Foreign Corp OwnershipYes (true)ForeignCorpOwnershipInd
Passive Foreign Investmest CoYes (true)PassiveForeignInvestmestCoInd
Foreign PartnershipfalseForeignPartnershipInd
Boycott CountriesfalseBoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE F, PAGE 1, PART I, LINE 2FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS.
SCHEDULE F, PAGE 1, PART I, LINE 3NORTH AMERICA 1,910,000 0 EUROPE 1,550,926 0 EUROPE 0 3,576,257 EAST ASIA 2,826,172 0 CENTRAL AMERICA & CARIBBEAN 0 1,735,772 MIDDLE EAST & NORTH AFRICA 120,000 0

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
Phone SolicitationsYes (X)PhoneSolicitationsInd
In Person SolicitationsYes (X)InPersonSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (true)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (5 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
RESOURCE ONE
2900 EAST APACHE STREETTULSAOK74110DIRECT MAIfalse$6,070,357-$6,070,357
MAIL AMERICA COMMUNICATIONS INC
PO BOX 870FORESTVA24551DIRECT MAIfalse$919,630-$919,630
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300LEXINGTONMA02421DIRECT MAIfalse$656,233-$656,233
THE HERITAGE COMPANY INC
PO BOX 16325LITTLE ROCKAR722316325DIRECT MAIfalse$225,963-$225,963
COINSTAR
1800 114TH AVENUE SEBELLEVUEWA98004COIN COLLEfalse$40,147-$40,147
FieldValueIRS element (for citing)
Total Retained By Contractors$7,912,330TotalRetainedByContractorsAmt
Total Net To Organization-$7,912,330TotalNetToOrganizationAmt
All StatesAll StatesAllStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1LAKE TAHOE BIKEEvent1Nm
Gross Receipts Event1$4,680,463GrossReceiptsEvent1Amt
Charitable Contri Event1$4,198,602CharitableContriEvent1Amt
Gross Revenue Event1$481,861GrossRevenueEvent1Amt
Non Cash Prizes Event1$254,582NonCashPrizesEvent1Amt
Rent Facility Costs Event1$24,254RentFacilityCostsEvent1Amt
Food And Beverage Event1$57,930FoodAndBeverageEvent1Amt
Entertainment Event1$11,805EntertainmentEvent1Amt
Other Direct Expenses Event1$425,128OtherDirectExpensesEvent1Amt
Event2SEATTLE BIG CLIEvent2Nm
Gross Receipts Event2$3,033,800GrossReceiptsEvent2Amt
Charitable Contri Event2$2,813,386CharitableContriEvent2Amt
Gross Revenue Event2$220,414GrossRevenueEvent2Amt
Non Cash Prizes Event2$150,135NonCashPrizesEvent2Amt
Rent Facility Costs Event2$47,068RentFacilityCostsEvent2Amt
Food And Beverage Event2$21,525FoodAndBeverageEvent2Amt
Entertainment Event2$2,082EntertainmentEvent2Amt
Other Direct Expenses Event2$1,791OtherDirectExpensesEvent2Amt
Other Events Total582OtherEventsTotalCnt
Gross Receipts Other Events$190,438,934GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$167,158,901CharitableContriOtherEventsAmt
Gross Revenue Other Events$23,280,033GrossRevenueOtherEventsAmt
Non Cash Prizes Other Events$5,356,182NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events$11,725,591RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events$4,741,230FoodAndBeverageOtherEventsAmt
Entertainment Other Events$1,160,802EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events$4,125,644OthDirectExpnssOtherEventsAmt
Gross Receipts Total$198,153,197GrossReceiptsTotalAmt
Charitable Contributions Tot$174,170,889CharitableContributionsTotAmt
Gross Revenue Total Events$23,982,308GrossRevenueTotalEventsAmt
Non Cash Prizes Total Events$5,760,899NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events$11,796,913RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events$4,820,685FoodAndBeverageTotalEventsAmt
Entertainment Total Events$1,174,689EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$4,552,563OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$28,105,749DirectExpenseSummaryEventsAmt
Net Income Summary-$4,123,441NetIncomeSummaryAmt

Gaming Information GamingInformationGrp

FieldValueIRS element (for citing)
Volunteer Labor BingofalseVolunteerLaborBingoInd
Volunteer Labor Pull TabsfalseVolunteerLaborPullTabsInd
Gross Revenue Other Gaming$560,287GrossRevenueOtherGamingAmt
Non Cash Prizes Other Gaming$227,233NonCashPrizesOtherGamingAmt
Volunteer Labor Other GamingYes (true)VolunteerLaborOtherGamingInd
Volunteer Labor Other Gaming0.90000VolunteerLaborOtherGamingPct
Gross Revenue Total Gaming$560,287GrossRevenueTotalGamingAmt
Non Cash Prizes Total Gaming$227,233NonCashPrizesTotalGamingAmt
Direct Expense Summary Gaming$227,233DirectExpenseSummaryGamingAmt
Net Gaming Income Summary$333,054NetGamingIncomeSummaryAmt
FieldValueIRS element (for citing)
States Where Gaming ConductedALStatesWhereGamingConductedCd
States Where Gaming ConductedDEStatesWhereGamingConductedCd
States Where Gaming ConductedDCStatesWhereGamingConductedCd
States Where Gaming ConductedNYStatesWhereGamingConductedCd
States Where Gaming ConductedOHStatesWhereGamingConductedCd
States Where Gaming ConductedORStatesWhereGamingConductedCd
States Where Gaming ConductedPAStatesWhereGamingConductedCd
States Where Gaming ConductedTXStatesWhereGamingConductedCd
States Where Gaming ConductedIAStatesWhereGamingConductedCd
LicensedYes (true)LicensedInd
License Suspended EtcfalseLicenseSuspendedEtcInd
Gaming With NonmembersfalseGamingWithNonmembersInd
Member Of Other EntityfalseMemberOfOtherEntityInd
Gaming Own Facility0.25000GamingOwnFacilityPct
Gaming Other Facility0.75000GamingOtherFacilityPct
Individual With BooksGORDON MILLER JRIndividualWithBooksNm

Persons With Books US Address PersonsWithBooksUSAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVE SUITE 200AddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Cntrct With3rd Prty For Game RevfalseCntrctWith3rdPrtyForGameRevInd
Gaming Manager PersonSEE SCHEDULE G PART IVGamingManagerPersonNm
Charitable Distribution RqrfalseCharitableDistributionRqrInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE G, PAGE 2, PART III, LINE 9TEXAS, IOWA
SCHEDULE G, PART IVSCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS, THOMPSON, HABIB & DENSION, AND THE HERITAGE COMPANY FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 20,178,168 DURING FISCAL YEAR 2018. LLS USED COINSTAR FOR ITS COIN COLLECTION DURING THE FISCAL YEAR 2018. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 16 THE LEUKEMIA AND LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF.

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Recipient Table RecipientTable (229 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtValuation Method UsedValuationMethodUsedDescPurpose Of GrantPurposeOfGrantTxtBusiness Name Line2RecipientBusinessName/BusinessNameLine2Txt
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$67,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$60,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF ALABAMA AT BIRMINGHAM
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF ARIZONA
1303 E UNIVERSITY BLVD BOX 3TUCSONAZ857217426526893$200,000ACCRUALRESEARCH GRANT
BANNER MD ANDERSON CANCER CENTER
2946 E BANNER GATEWAY DRIVEGILBERTAZ852347460011183$250,000FMVTHERAPY ACCELERATION
UNIVERSITY OF ARKANSAS FOR MEDICAL
4301 W MARKHAM SLOT 545LITTLE ROCKAR722057160567743$300,000ACCRUALRESEARCH GRANT
FORTY SEVEN INC
1490 OBRIEN DRIVE SUITE AMENLO PARKCA94025474065674$2,925,000FMVTHERAPY ACCELERATION
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$110,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$72,412ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$110,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$110,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$125,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$125,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$200,000ACCRUALRESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$1,000,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$110,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$65,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$67,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$55,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$60,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$60,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$60,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$200,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$200,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$200,000ACCRUALRESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$100,000ACCRUALRESEARCH GRANT
CHILDREN'S HOSPITAL LOS ANGELES
4650 SUNSET BLVD MAIL STOP 54LOS ANGELESCA900279516909773$200,000ACCRUALRESEARCH GRANT
LA JOLLA INSTITUTE FOR ALLERGY AND
9420 ATHENA CIRCLELA JOLLACA920373303286883$60,000ACCRUALRESEARCH GRANT
SANFORD BURNHAM PREBYS MEDICAL DISC
10901 NORTH TORREY PINES ROADLA JOLLACA920375101971083$60,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
11000 KINROSS AVE SUITE 102LOS ANGELESCA900959560061433$55,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
BOX 0897 1855 FOLSOM STREET SUITELOS ANGELESCA9007448729460364933$60,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
BOX 0897 1855 FOLSOM STREET SUITELOS ANGELESCA9007448729460364933$200,000ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
BOX 0897 1855 FOLSOM STREET SUITELOS ANGELESCA9007448729460364933$97,288ACCRUALRESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
BOX 0897 1855 FOLSOM STREET SUITELOS ANGELESCA9007448729460364933$300,000ACCRUALRESEARCH GRANT
THE SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD TPC-7LA JOLLACA920373304359543$60,000ACCRUALRESEARCH GRANT
THE SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD TPC-7LA JOLLACA920373304359543$75,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
BOX 0897 1855 FOLSOM STREET SUITELOS ANGELESCA9007448729460364933$55,000ACCRUALRESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
BOX 0897 1855 FOLSOM STREET SUITELOS ANGELESCA9007448729460364933$60,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
PO BOX 208327NEW HAVENCT0652018730606469733$62,500ACCRUALRESEARCH GRANT
YALE UNIVERSITY
PO BOX 208327NEW HAVENCT0652018730606469733$67,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
PO BOX 208327NEW HAVENCT0652018730606469733$60,000ACCRUALRESEARCH GRANT
YALE UNIVERSITY
PO BOX 208327NEW HAVENCT0652018730606469733$200,000ACCRUALRESEARCH GRANT
NEMOURS ALFRED I DUPONT HOSPITAL F
PO BOX 414876WILMINGTONDE198035906344333$117,181ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
33 TIGERT HALL P O BOX 113001GAINESVILLEFL3261130015960020523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF FLORIDA
33 TIGERT HALL P O BOX 113001GAINESVILLEFL3261130015960020523$67,000ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
1599 CLIFTON RD NE 4TH FL 1599-0ATLANTAGA3119350845821379933$67,000ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
1599 CLIFTON RD NE 4TH FL 1599-0ATLANTAGA3119350845821379933$200,000ACCRUALRESEARCH GRANT
EMORY UNIVERSITY
1599 CLIFTON RD NE 4TH FL 1599-0ATLANTAGA3119350845821379933$200,000ACCRUALRESEARCH GRANT
H LEE MOFFITT CANCER CENTER & RESE
PO BOX 742801ATLANTAGA3037428015932386343$449,155ACCRUALRESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
PO BOX 402420ATLANTAGA3038424205660013933$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
PO BOX 402420ATLANTAGA3038424205660013933$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$100,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$2,000,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$150,000ACCRUALRESEARCH GRANT
NORTHWESTERN UNIVERSITY
633 CLARK - ROOM G547EVANSTONIL602083621678173$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$67,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$60,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$200,000ACCRUALRESEARCH GRANT
THE BOARD OF TRUSTEES OF THE UNIVER
1901 SOUTH FIRST STREET SUITE ACHAMPAIGNIL618013760005113$52,457ACCRUALRESEARCH GRANT
THE UNIVERSITY OF IOWA
DIVISION OF SPONSORED PROGRAMS GILMIOWA CITYIA522424260048133$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF IOWA
DIVISION OF SPONSORED PROGRAMS GILMIOWA CITYIA522424260048133$200,000ACCRUALRESEARCH GRANT
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE ROOM M557BOSTONMA0221554500422630403$83,325FMVTHERAPY ACCELERATION
CONSTELLATION PHARMACEUTICALS INC
215 FIRST STREET SUITE 200CAMBRIDGEMA02142261741721$150,000FMVTHERAPY ACCELERATION
CHILDREN'S RESEARCH INSTITUTE
801 ROEDER RD SUITE 500SILVER SPRINGMD209105216404033$200,000ACCRUALRESEARCH GRANT
CHILDREN'S RESEARCH INSTITUTE
801 ROEDER RD SUITE 500SILVER SPRINGMD209105216404033$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MARYLAND BALTIMORE
PO BOX 41428BALTIMOREMD2120364285260020333$300,000ACCRUALRESEARCH GRANT
NATIONAL CANCER INSTITUTE
9000 ROCKVILLE PIKE BUILDING 12N210BETHESDAMD208921319197153$60,000ACCRUALRESEARCH GRANT
NEXIMMUNE INC
9119 GAITHER RDGAITHERSBURGMD20877$325,804FMVTHERAPY ACCELERATION
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$109,999ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$110,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$67,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$55,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$55,000ACCRUALRESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$200,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224144130427744413$110,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224144130427744413$67,000ACCRUALRESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149BOSTONMA0224144130427744413$200,000ACCRUALRESEARCH GRANT
BROAD INSTITUTE INC
7 CAMBRIDGE CENTERBOSTONMA0224144130427744413$60,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$107,643ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$110,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$109,981ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$43,306ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$125,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$125,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$62,500ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$67,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$29,991ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$55,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$60,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$60,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$60,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$199,999ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$200,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$1,150,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$75,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$300,000ACCRUALRESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUEBOSTONMA022150422630403$133,333ACCRUALRESEARCH GRANT
HARVARD MEDICAL SCHOOL
PO BOX 415649BOSTONMA0224156490421035803$60,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
PO BOX 414876BOSTONMA0224148760415646553$110,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
PO BOX 414876BOSTONMA0224148760415646553$55,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
PO BOX 414876BOSTONMA0224148760415646553$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
PO BOX 414876BOSTONMA0224148760415646553$200,000ACCRUALRESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
PO BOX 414876BOSTONMA0224148760415646553$75,000ACCRUALRESEARCH GRANT
MASSACHUSETTS INSTITUTE OF TECHNOLO
77 MASSACHUSETTS AVE NE18-901CAMBRIDGEMA021390421035943$200,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$110,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$93,712ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$60,000ACCRUALRESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 LAKE AVENUE NORTHWORCESTERMA0165500020431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 LAKE AVENUE NORTHWORCESTERMA0165500020431673523$110,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 LAKE AVENUE NORTHWORCESTERMA0165500020431673523$75,000ACCRUALRESEARCH GRANT
WHITEHEAD INSTITUTE FOR BIOMEDICAL
455 MAIN STREETCAMBRIDGEMA021420610434123$75,000ACCRUALRESEARCH GRANT
INDIANA UNIVERSITY
509 E 3RD STREETDETROITMI4827808673560189403$110,000ACCRUALRESEARCH GRANT
VAN ANDEL RESEARCH INSTITUTE
333 BOSTWICK AVE NEGRAND RAPIDSMI495035220008203$67,711ACCRUALRESEARCH GRANT
WESTERN MICHIGAN UNIVERSITY HOMOR S
PO BOX 50391KALAMAZOOMI4900503914541352563$67,000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
PO BOX 860334MINNEAPOLISMN5548603344160117023$200,000ACCRUALRESEARCH GRANT
MAYO CLINIC ROCHESTER
PO BOX 860334MINNEAPOLISMN5548603344160117023$200,000ACCRUALRESEARCH GRANT
UNIVERSITY OF MINNESOTA TWIN CITIE
450 MCNAMARA ALUMNI CENTERMINNEAPOLISMN554144160075133$200,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRST LOUISMO631124306536113$109,281ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRST LOUISMO631124306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DRST LOUISMO631124306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$110,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$200,000ACCRUALRESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$200,000ACCRUALRESEARCH GRANT
HACKENSACK MERIDIAN HEALTH
40 PROSPECT AVENUEHACKENSACKNJ076015417740393$110,000ACCRUALRESEARCH GRANT
HACKENSACK MERIDIAN HEALTH
40 PROSPECT AVENUEHACKENSACKNJ076013$149,985ACCRUALRESEARCH GRANT54-1774039
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVE BELFER 1108BRONXNY104614722090563$109,622ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVE BELFER 1108BRONXNY104614722090563$110,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVE BELFER 1108BRONXNY104614722090563$60,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVE BELFER 1108BRONXNY104614722090563$200,000ACCRUALRESEARCH GRANT
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVE BELFER 1108BRONXNY104614722090563$199,980ACCRUALRESEARCH GRANT
COLD SPRING HARBOR LABORATORY
1 BUNGTOWN ROAD PO BOX 100COLD SPRING HARBORNY117241120133033$106,333ACCRUALRESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ONE GUSTAVE L LEVY PLACE BOX 350NEW YORKNY100291361711973$110,000ACCRUALRESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ONE GUSTAVE L LEVY PLACE BOX 350NEW YORKNY100291361711973$110,000ACCRUALRESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ONE GUSTAVE L LEVY PLACE BOX 350NEW YORKNY100291361711973$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$100,528ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$67,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$60,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$60,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$200,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$400,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$300,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$1,000,000ACCRUALRESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$300,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$110,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$67,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$67,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$67,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$67,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$67,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$55,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$59,999ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$60,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$200,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$333,333ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$200,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$1,000,000ACCRUALRESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$100,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$109,997ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$67,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$67,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$60,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$500,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$50,000ACCRUALRESEARCH GRANT
ATRIUM HEALTH FOUNDATION
208 EAST BOULEVARD ATTN ELECTA MCPCHARLOTTENC282035660604813$110,000ACCRUALRESEARCH GRANT
COLUMBIA UNIVERSITY
615 WEST 131ST STREET - MAIL CODE 8NEW YORKNY100271355980933$120,000FMVTHERAPY ACCELERATION
WEILL CORNELL MEDICINE
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$900,000FMVTHERAPY ACCELERATION
STEMLINE THERAPEUTICS INC
750 LEXINGTON AVENUE 11TH FLOORNEW YORKNY10022450522567$500,000FMVTHERAPY ACCELERATION
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUECINCINATTIOH452293108339363$110,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUECINCINATTIOH452293108339363$67,000ACCRUALRESEARCH GRANT
CINCINNATI CHILDREN'S RESEARCH FOUN
3333 BURNET AVENUECINCINNATIOH452293108339363$200,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROADCOLUMBUSOH4321010163160259863$110,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROADCOLUMBUSOH4321010163160259863$200,000ACCRUALRESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROADCOLUMBUSOH4321010163160259863$200,000ACCRUALRESEARCH GRANT
CASE WESTERN
10900 EUCLID AVENUE BIOENTERPRISE BCLEVELANDOH4410670373410189923$200,000FMVTHERAPY ACCELERATION
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROAD MAILPORTLANDOR972392370831143$125,000ACCRUALRESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROAD MAILPORTLANDOR972392370831143$200,000ACCRUALRESEARCH GRANT
INSTITUTE FOR CANCER RESEARCH DBA
333 COTTMAN AVENUEPHILADELPHIAPA1911124342320030723$200,000ACCRUALRESEARCH GRANT
PERELMAN SCHOOL OF MEDICINE AT THE
3451 WALNUT STREET FRANKLIN BLDG P-PHILADELPHIAPA1910462052313526853$110,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$109,882ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$60,000ACCRUALRESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$200,000ACCRUALRESEARCH GRANT
TEMPLE UNIVERSITY
PO BOX 824242PHILADELPHIAPA1918242422313659713$200,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
LOCKBOX 1457 PO BOX 8500PHILADELPHIAPA1917814572313521663$200,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
LOCKBOX 1457 PO BOX 8500PHILADELPHIAPA1917814572313521663$200,000ACCRUALRESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREET FRANKLIN BLDG P-PHILADELPHIAPA1910462052313526853$51,895ACCRUALRESEARCH GRANT
THE WISTAR INSTITUTE
3601 SPRUCE STREETPHILADELPHIAPA191042364343903$60,000ACCRUALRESEARCH GRANT
UNIVERSITY OF PITTSBURGH
500 ROSS STREET 154-0455PITTSBURGPA1526200012509655913$65,000ACCRUALRESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
1901 SOUTH FIRST STREET SUITE APHILADELPHIAPA1917814572313521663$100,000ACCRUALRESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
PO BOX 1000 DEPT 949MEMPHISTN3814809496206460123$110,000ACCRUALRESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
PO BOX 1000 DEPT 949MEMPHISTN3814809496206460123$65,518ACCRUALRESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
PO BOX 1000 DEPT 949MEMPHISTN3814809496206460123$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
P O BOX 301207DALLASTX7530312077416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
P O BOX 301207DALLASTX7530312077416138783$200,000ACCRUALRESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
P O BOX 301207DALLASTX7530312077416138783$100,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS HEALTH SCIE
MAIL CODE 78287703 FLOYD CURL DRIVESAN ANTONIOTX7822939007415860313$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$200,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$199,924ACCRUALRESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$2,000,000ACCRUALRESEARCH GRANT
VANDERBILT UNIVERSITY MEDICAL CENTE
DEPT 1236 PO BOX 121236DALLASTX753126204768223$125,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145SALT LAKE CITYUT8411290038760005253$110,000ACCRUALRESEARCH GRANT
THE UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145SALT LAKE CITYUT8411290038760005253$67,000ACCRUALRESEARCH GRANT
UNIVERSITY OF VIRGINIA
PO BOX 400195CHARLOTTESVILLEVA2290441952371734113$110,000ACCRUALRESEARCH GRANT
VIRGINIA COMMONWEALTH UNIVERSITY
PO BOX 843039RICHMONDVA2328430395460017583$300,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$110,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$110,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$67,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$200,000ACCRUALRESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300SEATTLEWA9810910242371560713$200,000ACCRUALRESEARCH GRANT
THE BOARD OF REGENTS OF THE UNIVERS
21 N PARK ST SUITE 6401MADISONWI5371512183960064923$200,000ACCRUALRESEARCH GRANT
TRAVERA
700 NORTH MAIN STREETCAMBRIDGEMA02139820655339$200,000FMVTHERAPY ACCELERATION
FieldValueIRS element (for citing)
Total501c3 Org78Total501c3OrgCnt
Total Other Org6TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (10 entries)

Grant TypeGrantTypeTxtRecipientRecipientCntCash GrantCashGrantAmt
COPAY ASSISTANCE CLL5608$18,808,624
COPAY ASSISTANCE LYMPHOMA8925$13,193,314
COPAY ASSISTANCE MDS1976$5,960,480
COPAY ASSISTANCE MYELOMA10351$56,804,404
COPAY ASSISTANCE MANTEL982$4,262,012
COPAY ASSISTANCE WALDENST1246$5,695,359
COPAY ASSISTANCE ALL106$310,000
COPAY ASSISTANCE AML655$3,265,498
COPAY ASSISTANCE CML49$142,791
PATIENT TRAVEL ASSISTNCE4772$2,007,419

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE I, PAGE 1, PART I, LINE 2FormAndLineReferenceDesc
ExplanationFIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentYes (true)SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (true)SupplementalNonqualRtrPlanInd
Equity Based Comp ArrngmfalseEquityBasedCompArrngmInd
Comp Based On Revenue Of Flng OrgfalseCompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related OrgsfalseCompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng OrgfalseCompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd OrgsfalseCompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (true)AnyNonFixedPaymentsInd
Initial Contract ExceptionfalseInitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtBonus Filing OrganizationBonusFilingOrganizationAmountOther Compensation Filing OrgOtherCompensationFilingOrgAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmt
LOUIS J DEGENNARO
PRESIDENT & CEO$531,927$78,000$24,754$17,010$21,596$673,287
ROSEMARIE A LOFFREDO
EVP - CFO$326,256$31,059$23,124$9,450$11,161$401,050
GORDON MILLER JR
SVP FINANCE$239,086$26,600$4,406$13,500$25,012$308,604
ANDREW S COCCARI
EVP CHIEF PROD OFFIC$325,696$29,689$1,702$9,450$29,167$395,704
ALICE O'ROURKE
EVP CHIEF DEV OFFICE$319,848$28,994$4,797$6,596$32,841$393,076
GWEN NICHOLS
EVP CHIEF MED OFFICE$313,116$60,000$3,988$22,429$399,533
KATHY GRISENBECK
EVP CHIEF REL OFFICE$289,432$28,726$6,055$12,633$22,371$359,217
LEE M GREENBERGER
SVP CHIEF SCIEN OFFI$287,763$33,056$8,870$9,450$32,950$372,089
CLAUDE EDKINS - END 3312017
VP INFORMATION TECHN$61,216$73,100$220,070$6,786$7,537$368,709
MARCIE KLEIN
EVP, COMMUNICATIONS$243,153$20,865$2,270$9,386$21,573$297,247
ELISA WEISS
SVP PAT ACCESS AND O$231,652$24,344$1,151$9,073$17,583$283,803
CARSON JACOBI
SVP, HEALTHCARE PART$217,117$23,243$10,644$12,709$18,330$282,043

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE J, PAGE 1, PART I, LINE 4LOUIS J. DEGENNARO 0 1 0 CLAUDE EDKINS - END 3/31/2017 220,070 0 0
SCHEDULE J, PAGE 1, PART I, LINE 7BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE EMPLOYEE INDIVIDUAL PERFORMANCE. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II).

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

FieldValueIRS element (for citing)
PersonCAITLIN PROCTORPersonNm
FieldValueIRS element (for citing)
Relationship DescriptionEMPLOYEERelationshipDescriptionTxt
Transaction$29,239TransactionAmt
TransactionDAUGHTER OF BOARD METransactionDesc
Sharing Of RevenuesfalseSharingOfRevenuesInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE L, PART VFormAndLineReferenceDesc
ExplanationCAITLIN PROCTOR WAS A COMPENSATED EMPLOYEE OF LLS BEGINNING FROM AUGUST 14, 2017 UNTIL MARCH 9, 2018, AND IS THE DAUGHTER OF DONALD PROCTOR, A CURRENT BOARD MEMBER OF LLS.ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution312ContributionCnt
Noncash Contributions Rpt F990$3,082,490NoncashContributionsRptF990Amt
Method Of Determining RevenuesMARKET VALUEMethodOfDeterminingRevenuesTxt

Food Inventory FoodInventoryGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution114ContributionCnt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxIndDescDescContributionContributionCntNoncash Contributions Rpt F990NoncashContributionsRptF990Amt
Yes (X)PRINTED ITEMS30
Yes (X)VARIOUS80$1,483,566
FieldValueIRS element (for citing)
Any Property That Must Be HeldfalseAnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (true)ReviewProcessUnusualNCGiftsInd
Third Parties UsedfalseThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE M, PAGE 2, PART IIFormAndLineReferenceDesc
ExplanationPART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (15 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PAGE 2, PART III, LINE 4AWE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2018, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 47 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA(AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. LLS EXPECTS UP TO 500 PATIENTS TO ENROLL IN THE TRIAL. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2018, FOR THE SEVENTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOLENT LYMPHOMA PATIENTS - DEFINE
FORM 990, PAGE 2, PART III, LINE 4BPROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2018, 621,651 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 7,449 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 102,125 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2018, A COMBINED 110,449,901 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAMS (108,442,482) AND THE LLS NATIONAL PATIENT TRAVEL ASSISTANCE PROGRAM, (2,007,419). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2018, 108,442,482 WAS PROVIDED TO PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. - 29,898 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2018. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2018, 2,007,419 WAS PROVIDED TO PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM 4,772 PATIENTS RECEIVED LLS TRAVEL ASSISTANCE IN 2018. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2018, 10 BCC CONFERENCES WERE HELD WITH 3,220 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2018, THERE WERE APPROXIMATELY 8,000 COMMUNITY MEMBERS AND 69,532 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 41,000 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2018 LLS SUPPORTED OR HOSTED 113 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2018, 3,382 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,300 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2018.
FORM 990, PAGE 2, PART III, LINE 4CCAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2018: - 18,453 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 12,643 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -562 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 60% OF MEDICALLY ELIGIBLE PATIENTS ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 18 NEARLY 1000 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2018: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 5,572 PARTICIPANTS -THERE WERE 29,756 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 12,004 VIRTUAL LECTURE VIEWS; 6,801 PODCAST DOWNLOADS; AND 32,708 VIDEO VIEWS. -LLS LAUNCHED A NEW PODCAST, "THE BLOODLINE WITH LLS," WHICH REACHED MORE THAN 7,000 LISTENERS AND COVERED A RANGE OF TOPICS THAT MATTER MOST TO PATIENTS AND CAREGIVERS, FROM CANCER-RELATED FATIGUE TO COMMUNICATING EFFECTIVELY WITH CANCER CARE TEAMS.
FORM 990, PAGE 2, PART III, LINE 4DD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2018: -LLS PROVIDED 11 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 1,981 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 18,503 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 12,919 VIRTUAL LECTURE VIEWS; AND 3,775 ONLINE VIDEO VIEWS FOR PROFESSIONALS.
FORM 990, PART V, LINE 4BCANADA
FORM 990, PAGE 6, PART VI, LINE 6THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER.
FORM 990, PAGE 6, PART VI, LINE 7ATHE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS.
FORM 990, PAGE 6, PART VI, LINE 7BSIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES.
FORM 990, PAGE 6, PART VI, LINE 11BTHE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS.
FORM 990, PAGE 6, PART VI, LINE 12CALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
FORM 990, PAGE 6, PART VI, LINE 15ATHE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2018 THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THEIR COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15BIN 2018, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS.
FORM 990, PAGE 6, PART VI, LINE 17ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.
FORM 990, PART XI, LINE 9LLS CANADA RESTATEMENT -262,119

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp

Disregarded Entity Name DisregardedEntityName

FieldValueIRS element (for citing)
Business Name Line1BEAT AML LLCBusinessNameLine1Txt

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Primary ActivitiesRESEARCHPrimaryActivitiesTxt
Legal Domicile StateNYLegalDomicileStateCd
Total Income$9,963,492TotalIncomeAmt
End Of Year Assets$12,544,354EndOfYearAssetsAmt

Direct Controlling Entity Name DirectControllingEntityName

FieldValueIRS element (for citing)
Business Name Line1LLSBusinessNameLine1Txt

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (4 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1TxtControlled OrganizationControlledOrganizationIndAddress Line1ForeignAddress/AddressLine1TxtCityForeignAddress/CityNmCountryForeignAddress/CountryCdForeign PostalForeignAddress/ForeignPostalCdLegal Domicile Foreign CountryLegalDomicileForeignCountryCd
THE LLS RESEARCH PROGRAMS INC
3 INTERNATIONAL DRIVERYE BROOKNY10573133470494PART VIIDE501C312ALLS INCYes (true)
THE LLS RESEARCH FOUNDATION
3 INTERNATIONAL DRIVERYE BROOKNY10573133709252PART VIIDE501C312ALLS INCYes (true)
THE LLS OF CANADA
PART VIINAfalse804 2 LANSING SQUARETORONTOCAM2J4P8CA
PEARLPOINT CANCER SUPPORT
2817 WEST END AVENUENASHVILLETN37203581747771PART VIITN501C37LLS INCYes (true)
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts RyltsfalseReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth OrgfalseGiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgfalseGiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other OrgfalseLoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth OrgfalseLoansOrGuaranteesFromOthOrgInd
Div Related OrganizationfalseDivRelatedOrganizationInd
Asset Sale To Other OrgfalseAssetSaleToOtherOrgInd
Asset Purchase From Other OrgfalseAssetPurchaseFromOtherOrgInd
Asset ExchangefalseAssetExchangeInd
Rental Of Facilities To Oth OrgfalseRentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth OrgfalseRentalOfFcltsFromOthOrgInd
Perform Of Services For Oth OrgYes (true)PerformOfServicesForOthOrgInd
Perform Of Services By Other OrgfalsePerformOfServicesByOtherOrgInd
Sharing Of FacilitiesfalseSharingOfFacilitiesInd
Paid Employees SharingYes (true)PaidEmployeesSharingInd
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other OrgYes (true)ReimbursementPaidByOtherOrgInd
Transfer To Other OrgfalseTransferToOtherOrgInd
Transfer From Other OrgfalseTransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (3 entries)

Transaction TypeTransactionTypeTxtInvolvedInvolvedAmtMethod Of Amount DeterminationMethodOfAmountDeterminationTxt
THE LLS OF CANADA
Q$260,005COST
PEARLPOINT CANCER SUPPORT
L$70,000COST
PEARLPOINT CANCER SUPPORT
O$90,967COST

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE RFormAndLineReferenceDesc
ExplanationTHE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC. THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IS THE 100% CONTROLLING MEMBER OF PEARLPOINT CANCER SUPPORT, INC.ExplanationTxt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.